Abbott Laboratories
ABT· NYSE
ABTAbbott Laboratories
Filed Feb 19, 2021 · 10-K · 50 days after period end · 0001104659-21-025751
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $10.70B | $8.31B | $7.77B | $7.59B |
| Net Income | $2.16B | $1.05B | $654.00M | -$828.00M |
| EPS Diluted | — | $0.59 | $0.37 | -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Feb 19, 2021 · 50 d after period end
